Tonix Pharmaceuticals (NASDAQ: TNXP) Promotes Siobhan Fogarty to Chief Technology Officer

Tonix Pharmaceuticals Holding Corp. recently announced the appointment of Siobhan Fogarty as the Chief Technology Officer of the company. The decision, effective from February 3, 2025, reflects the Board of Directors’ confidence in Fogarty’s capabilities and contributions to Tonix Pharmaceuticals.

Siobhan Fogarty, aged 56, has been associated with Tonix Pharma Limited, a subsidiary of the Company, since September 2016. Over the years, she has held various roles within the organization, with her most recent position as the Executive Vice President of Product Development starting in February 2021. Fogarty’s extensive experience includes a Bachelor of Science in Industrial Chemistry from the University of Limerick and a Masters in Pharmaceutical Science from Trinity College Dublin.

There are no undisclosed agreements or familial relationships influencing Ms. Fogarty’s appointment. Additionally, she is not party to any transactions necessitating disclosure under Item 404(a) of Regulation S-K.

In tandem with the internal promotion, a press release was issued on February 4, 2025, detailing Fogarty’s elevation to Chief Technology Officer. The successful progression of Fogarty showcases Tonix Pharmaceuticals’ dedication to nurturing talent within its ranks.

Moreover, Tonix Pharmaceuticals’ press release further highlighted the strategic importance of Ms. Fogarty’s role in the context of the company’s upcoming milestones. The focus notably remains on the potential launch of TNX-102 SL, a product candidate aimed at managing fibromyalgia, with a critical U.S. FDA PDUFA goal date set for August 15, 2025.

Siobhan Fogarty’s remarkable journey from her initial role at Elan Corporation to her current appointment as Chief Technology Officer exemplifies Tonix Pharmaceuticals’ commitment to fostering talent and expertise within the organization. Her extensive background in pharmaceutical and biotech product development positions her as a valuable asset for Tonix Pharmaceuticals during this pivotal phase.

The company underlines that the information disclosed in this report shall not be considered as filed under Section 18 of the Securities Exchange Act of 1934. Furthermore, it clarifies that the content provided should not be incorporated by reference in any future filings under the United States Securities Act of 1933 or the Exchange Act unless specifically stipulated.

With Tonix Pharmaceuticals gearing up for a momentous period marked by key developments and strategic initiatives, Siobhan Fogarty’s promotion to Chief Technology Officer signals a significant advancement within the company’s leadership structure. Her experience and expertise are expected to play a crucial role in steering Tonix Pharmaceuticals towards its strategic goals and milestones in the coming years.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Tonix Pharmaceuticals’s 8K filing here.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.